A detailed history of Susquehanna International Group, LLP transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Susquehanna International Group, LLP holds 260,821 shares of CRSP stock, worth $14.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
260,821
Previous 73,238 256.13%
Holding current value
$14.3 Million
Previous $4.99 Million 182.23%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

BUY
$51.17 - $68.18 $9.6 Million - $12.8 Million
187,583 Added 256.13%
260,821 $14.1 Million
Q1 2024

May 07, 2024

SELL
$60.67 - $89.12 $8.73 Million - $12.8 Million
-143,858 Reduced 66.26%
73,238 $4.99 Million
Q4 2023

Feb 14, 2024

BUY
$38.62 - $72.18 $1.33 Million - $2.49 Million
34,531 Added 18.91%
217,096 $13.6 Million
Q3 2023

Nov 14, 2023

BUY
$45.39 - $59.0 $855,419 - $1.11 Million
18,846 Added 11.51%
182,565 $8.29 Million
Q2 2023

Aug 11, 2023

SELL
$43.47 - $67.77 $5.78 Million - $9.02 Million
-133,070 Reduced 44.84%
163,719 $9.19 Million
Q1 2023

May 16, 2023

BUY
$41.0 - $56.12 $8.81 Million - $12.1 Million
214,882 Added 262.35%
296,789 $13.4 Million
Q4 2022

Feb 14, 2023

BUY
$39.19 - $65.67 $1.57 Million - $2.63 Million
40,084 Added 95.84%
81,907 $3.33 Million
Q3 2022

Nov 14, 2022

BUY
$61.1 - $83.78 $305,866 - $419,402
5,006 Added 13.6%
41,823 $2.73 Million
Q2 2022

Aug 15, 2022

SELL
$43.23 - $73.83 $8.99 Million - $15.4 Million
-207,914 Reduced 84.96%
36,817 $2.24 Million
Q1 2022

May 16, 2022

SELL
$53.19 - $79.24 $17.6 Million - $26.3 Million
-331,716 Reduced 57.54%
244,731 $15.4 Million
Q4 2021

Feb 14, 2022

BUY
$70.09 - $111.29 $12.1 Million - $19.3 Million
173,303 Added 42.99%
576,447 $43.7 Million
Q3 2021

Nov 15, 2021

BUY
$110.2 - $156.64 $5.62 Million - $7.98 Million
50,971 Added 14.47%
403,144 $45.1 Million
Q2 2021

Aug 11, 2021

SELL
$100.84 - $161.89 $9.75 Million - $15.7 Million
-96,716 Reduced 21.55%
352,173 $57 Million
Q1 2021

May 17, 2021

BUY
$110.72 - $210.04 $31.3 Million - $59.4 Million
282,629 Added 169.99%
448,889 $54.7 Million
Q4 2020

Feb 16, 2021

BUY
$79.67 - $173.23 $6.96 Million - $15.1 Million
87,299 Added 110.56%
166,260 $25.5 Million
Q3 2020

Nov 16, 2020

SELL
$78.5 - $100.64 $8.25 Million - $10.6 Million
-105,081 Reduced 57.1%
78,961 $6.6 Million
Q2 2020

Aug 14, 2020

SELL
$38.5 - $76.05 $768,267 - $1.52 Million
-19,955 Reduced 9.78%
184,042 $13.5 Million
Q1 2020

May 15, 2020

BUY
$33.68 - $62.53 $215,417 - $399,941
6,396 Added 3.24%
203,997 $8.65 Million
Q4 2019

Feb 14, 2020

BUY
$36.68 - $73.13 $2.77 Million - $5.53 Million
75,631 Added 62.01%
197,601 $12 Million
Q3 2019

Nov 14, 2019

SELL
$40.99 - $52.56 $2.48 Million - $3.18 Million
-60,477 Reduced 33.15%
121,970 $5 Million
Q2 2019

Aug 16, 2019

BUY
$35.45 - $48.2 $118,367 - $160,939
3,339 Added 1.86%
182,447 $8.59 Million
Q2 2019

Aug 14, 2019

SELL
$35.45 - $48.2 $444,897 - $604,910
-12,550 Reduced 6.55%
179,108 $8.44 Million
Q1 2019

May 15, 2019

SELL
$28.02 - $40.87 $374,263 - $545,900
-13,357 Reduced 6.52%
191,658 $6.85 Million
Q4 2018

Feb 14, 2019

SELL
$22.73 - $42.34 $3 Million - $5.59 Million
-131,945 Reduced 39.16%
205,015 $5.86 Million
Q3 2018

Nov 14, 2018

BUY
$44.35 - $65.71 $6.52 Million - $9.66 Million
147,022 Added 77.41%
336,960 $14.9 Million
Q2 2018

Aug 14, 2018

BUY
$42.62 - $73.59 $1.4 Million - $2.41 Million
32,748 Added 20.83%
189,938 $11.2 Million
Q1 2018

May 15, 2018

BUY
$23.52 - $58.17 $2.98 Million - $7.36 Million
126,589 Added 413.68%
157,190 $7.19 Million
Q4 2017

Feb 14, 2018

BUY
$16.95 - $23.48 $106,412 - $147,407
6,278 Added 25.81%
30,601 $719,000
Q3 2017

Nov 14, 2017

BUY
$16.75 - $20.66 $407,410 - $502,513
24,323
24,323 $435,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $4.28B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.